Nurix Therapeutics has enrolled the first patient in its global Phase 3 DAYBreak CLL-306 trial, comparing bexobrutideg, a targeted protein degrader, to pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who previously received a covalent BTK inhibitor. This trial aims to show bexobrutideg's superiority in effectiveness and safety, potentially offering a new treatment option for patients with limited choices. Approximately 620 patients will be randomized to receive either bexobrutideg or pirtobrutinib, with key measures including response rate and progression-free survival. The study is a significant step in developing next-generation therapies for CLL/SLL and could impact future regulatory approvals.
Ed Stafford, famed explorer and Discovery Channel host, has become a global owner of the JETOUR G700 SUV, marking a partnership to co-produce Season 2 of JETOUR’s Adventure of Extremes. The vehicle handover ceremony was held with top executives from ...
The latest episode of Troutman Amin, LLP's Deserve to Win Podcast features interviews with CEOs from Contact Center Compliance, PureCaller ID, and Sonera, discussing the merger of CCC and PCID into Sonera and its impact on telecom industry consolidat...
The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as six weeks old to protect against invasive meningococcal disease caused by serogroups A, C, W, and Y. Previously approved for those aged 12 months and older...
IQM Quantum Computers announced its first half and second quarter 2026 financial results, reporting EUR 8.9 million in revenues and an operating loss of EUR 60.5 million. The company has a robust order backlog exceeding EUR 102 million as of August 3...
Wix.com reported Q2 2026 revenue of $563 million, up 15% year-over-year, fueled by strong performance from its Base44 AI app-creation platform and core Wix growth. Base44 launched its proprietary large language model, Base 1, which significantly lowe...
